Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial
Electronic Patient Reporting of Side Effects to Chemotherapy Among Breast Cancer Patients Using the Patient-Reported Outcomes Version of Common Terminology Criteria for Adverse Events (PRO-CTCAE): A Cluster Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Gender •Female: only female participants are being studied
Minimum age
•18 years
Maximum age •N/A
Accepts Healthy Volunteers
•No
Eligibility Criteria
Inclusion criteria
- Breast cancer patients starting adjuvant chemotherapy in the period November 1, 2015 - September 1, 2016 in Danish oncology clinics
Exclusion Criteria:
- More than six scheduled cycles of chemotherapy
- Not able to read and understand Danish language
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Electronic reporting of PRO-CTCAE items
Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
|
Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
|
|
No Intervention: Standard practice
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Dose adjustments reported in the medication treatment sheet before each cycle of chemotherapy (5 time points with three weeks interval)
Time Frame: up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017
|
up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of hospitalizations reported in the medical record after each of the six cycles of chemotherapy
Time Frame: up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017
|
up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017
|
|
Febrile neutropenia reported in the medical record after each of the six cycles of chemotherapy
Time Frame: up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017
|
up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017
|
|
Detailed description of side effects in the medical record before start of chemotherapy and after each six cycles of chemotherapy
Time Frame: up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017
|
up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017
|
|
Handling of side effects documented in the medical record
Time Frame: up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017
|
up to 18 weeks of treatment in the period betweeen November 1, 2015 and January 31, 2017
|
|
Patients' experience of communication and handling of side effects measured in questionnaire survey and qualitative interviews
Time Frame: up to18 weeks of chemotherapy in the period November 1, 2015 - January 31, 2017
|
up to18 weeks of chemotherapy in the period November 1, 2015 - January 31, 2017
|
|
Patient and staff compliance as registerede by the software used
Time Frame: up to 18 weeks (November 1, 2015 - January 31, 2017)
|
up to 18 weeks (November 1, 2015 - January 31, 2017)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Pappot H, Baeksted CW, Nissen A, Knoop A, Mitchell SA, Christensen J, Hjollund NH, Johansen C. Clinical effects of assessing electronic patient-reported outcomes monitoring symptomatic toxicities during breast cancer therapy: a nationwide and population-based study. Breast Cancer. 2021 Sep;28(5):1096-1099. doi: 10.1007/s12282-021-01244-x. Epub 2021 Apr 9.
- Baeksted CW, Nissen A, Knoop AS, Pappot H. Patients' experience of communication and handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy. Res Involv Engagem. 2019 Nov 20;5:36. doi: 10.1186/s40900-019-0171-1. eCollection 2019.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- R113-A7084-14-S34
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.